These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23675648)

  • 1. Antisense oligonucleotides for therapeutic interventions in neuromuscular diseases.
    Danos O
    Hum Gene Ther; 2013 May; 24(5):470-1. PubMed ID: 23675648
    [No Abstract]   [Full Text] [Related]  

  • 2. Opportunities and challenges for the development of antisense treatment in neuromuscular disorders.
    van Putten M; Aartsma-Rus A
    Expert Opin Biol Ther; 2011 Aug; 11(8):1025-37. PubMed ID: 21510827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromuscular diseases: hope and hurdles in clinical trials.
    Verschuuren JJ
    Lancet Neurol; 2017 Jan; 16(1):12-13. PubMed ID: 27979339
    [No Abstract]   [Full Text] [Related]  

  • 4. An update on RNA-targeting therapies for neuromuscular disorders.
    Jirka S; Aartsma-Rus A
    Curr Opin Neurol; 2015 Oct; 28(5):515-21. PubMed ID: 26280937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Principles of translational gene therapy for neuromuscular diseases].
    Schoser B
    Nervenarzt; 2022 Jun; 93(6):537-548. PubMed ID: 35384490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis.
    van der Bent ML; Paulino da Silva Filho O; van Luijk J; Brock R; Wansink DG
    Sci Rep; 2018 Mar; 8(1):4181. PubMed ID: 29520012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotide technology: from EST to therapeutics.
    Giles RV
    Curr Opin Mol Ther; 2000 Jun; 2(3):238-52. PubMed ID: 11249617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides.
    Akhavein N; Oettinger CW; Gayakwad SG; Addo RT; Bejugam NK; Bauer JD; Do D; Pollock SH; D'souza MJ
    J Microencapsul; 2009 May; 26(3):223-34. PubMed ID: 18666015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA-targeting approaches for neuromuscular diseases.
    Le Roy F; Charton K; Lorson CL; Richard I
    Trends Mol Med; 2009 Dec; 15(12):580-91. PubMed ID: 19906562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligonucleotides--from design to the clinic.
    Bennett CF
    Curr Opin Mol Ther; 1999 Jun; 1(3):296. PubMed ID: 11713793
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making antisense of splicing.
    Garcia-Blanco MA
    Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.
    Miyake H; Hara I; Fujisaw M; Gleave ME
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1001-9. PubMed ID: 16336091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advantages of antisense drugs for the treatment of oral diseases.
    Nedbal W; Teichmann B
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):183-91. PubMed ID: 12162701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antisense oligonucleotides in the treatment of bladder cancer.
    Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
    Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Organization of therapeutic aid to patients with hereditary neuromuscular diseases].
    Kalinin VA; Temin PA; Arkhipov BA; Zavadenko NN
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(12):26-9. PubMed ID: 2633564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-conjugated antisense therapy takes a skip ahead.
    Wells DJ
    Mol Ther; 2008 Sep; 16(9):1523-4. PubMed ID: 18725878
    [No Abstract]   [Full Text] [Related]  

  • 20. Hybridon and Aegera collaborate to develop antisense drug.
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):483-4. PubMed ID: 12382515
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.